← ANALYST RATINGS · TIPRANKS
Regeneron (REGN): analyst forecast and price target
Analyst consensus
Moderate Buy11 Buy7 Hold0 Sell
Ratings of 18 analysts in the last 3 months · top analysts only12-month forecast
Based on 18 price targets given in the last 3 months, the average target is $864, the highest $1,030, the lowest $740. The average is +9.3% from the last price of $791.
Analyst ratings 48
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% | Wells Fargo | $750 | Hold | −5.2% | Reiterated | 15.10.26on TipRanks 07:30 | +2.0%next day +0.4% | ↗ |
| Joon Lee★★★★★★★★★★#73 · hits 58% · avg +36.3% | Truist Financial | $660 → $978+48.2% | Buy | +23.7% | Initiated | 14.10.26on TipRanks 19:50 | +2.0%next day +0.4% | ↗ |
| Louise Chen★★★★★★★★★★#1899 · hits 52% · avg +5.9% | Scotiabank | $770 | Hold | −2.6% | Reiterated | 14.10.26on TipRanks 07:50 | +4.4%next day +2.0% | ↗ |
| Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% | BMO Capital | $920 | Buy | +16.3% | Reiterated | 12.10.26on TipRanks 08:55 | +2.2%next day −1.3% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $891 → $908+1.9% | Buy | +14.8% | Reiterated | 12.10.26on TipRanks 06:50 | +2.2%next day −1.3% | ↗ |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $740 | Hold | −6.4% | Reiterated | 12.10.26on TipRanks 06:15 | +2.2%next day −1.3% | ↗ |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $737 → $810+9.9% | Hold | +2.4% | Reiterated | 08.10.26on TipRanks 08:55 | +0.1%next day +0.3% · 5 days +8.0% | ↗ |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | $772 → $780+1.0% | Buy | −1.4% | Reiterated | 07.10.26on TipRanks 09:05 | +0.7%next day +0.1% · 5 days +5.9% | ↗ |
| Terence Flynn★★★★★★★★★★#815 · hits 60% · avg +10.8% | Morgan Stanley | $779 | Hold | −1.5% | Reiterated | 07.10.26on TipRanks 08:15 | +0.7%next day +0.1% · 5 days +5.9% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $852 → $821−3.6% | Buy | +3.8% | Reiterated | 06.10.26on TipRanks 16:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $841 → $814−3.2% | Buy | +2.9% | Reiterated | 06.10.26on TipRanks 16:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $848 → $806−5.0% | Buy | +1.9% | Reiterated | 06.10.26on TipRanks 16:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $826 → $803−2.8% | Buy | +1.6% | Reiterated | 06.10.26on TipRanks 16:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $856 → $835−2.5% | Buy | +5.6% | Reiterated | 06.10.26on TipRanks 16:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $875 → $845−3.4% | Buy | +6.9% | Reiterated | 06.10.26on TipRanks 16:05 | — | |
| Chris Schott★★★★★★★★★★#1915 · hits 58% · avg +5.7% | J.P. Morgan | $900 → $950+5.6% | Buy | +20.1% | Assigned | 06.10.26on TipRanks 07:10 | +1.1%next day +0.7% · 5 days +2.1% | ↗ |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $740 | Hold | −6.4% | Reiterated | 02.10.26on TipRanks Oct 5 08:12 | −0.7%next day −1.9% · 5 days +0.4% | ↗ |
| Brian Skorney★★★★★★★★★★#12116 · hits 37% · avg −5.6% | Robert W. Baird | $761 | Hold | −3.8% | Reiterated | 02.10.26on TipRanks 09:15 | −0.7%next day −1.9% · 5 days +0.4% | ↗ |
| David Risinger★★★★★★★★★★#64 · hits 65% · avg +33.1% | Leerink Partners | — | Hold | — | Reiterated | 02.10.26on TipRanks 08:15 | −0.7%next day −1.9% · 5 days +0.4% | ↗ |
| Biren Amin★★★★★★★★★★#1671 · hits 46% · avg +7.6% | Piper Sandler | $854 | Buy | +8.0% | Reiterated | 02.10.26on TipRanks 07:35 | −0.7%next day −1.9% · 5 days +0.4% | ↗ |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | $772 | Buy | −2.4% | Reiterated | 02.10.26on TipRanks 07:35 | −0.7%next day −1.9% · 5 days +0.4% | ↗ |
| Louise Chen★★★★★★★★★★#1899 · hits 52% · avg +5.9% | Scotiabank | $770 | Hold | −2.6% | Reiterated | 02.10.26on TipRanks 07:25 | −0.7%next day −1.9% · 5 days +0.4% | ↗ |
| Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% | Barclays | $917 | Buy | +16.0% | Reiterated | 02.10.26on TipRanks 04:45 | −0.7%next day −1.9% · 5 days +0.4% | ↗ |
| Salveen Richter★★★★★★★★★★#967 · hits 51% · avg +12.5% | Goldman Sachs | $972 | Buy | +22.9% | Reiterated | 01.10.26on TipRanks Oct 2 08:55 | −3.3%next day −0.7% · 5 days −0.7% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $891 | Buy | +12.7% | Reiterated | 01.10.26on TipRanks Oct 2 05:10 | −3.3%next day −0.7% · 5 days −0.7% | ↗ |
| Akash Tewari★★★★★★★★★★#649 · hits 57% · avg +13.5% | Jefferies | $870 → $930+6.9% | Buy | +17.6% | Reiterated | 01.10.26on TipRanks 13:10 | −3.3%next day −0.7% · 5 days −0.7% | ↗ |
| Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% | BMO Capital | $800 → $920+15.0% | Buy | +16.3% | Reiterated | 01.10.26on TipRanks 07:15 | −3.3%next day −0.7% · 5 days −0.7% | ↗ |
| Jasper Hellweg★★★★★★★★★★#2291 · hits 57% · avg +7.4% | Argus Research | $850 | Buy | +7.5% | Upgrade | 01.10.26on TipRanks 07:08 | −3.3%next day −0.7% · 5 days −0.7% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $803 → $852+6.1% | Buy | +7.7% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $810 → $841+3.8% | Buy | +6.4% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $800 → $848+6.0% | Buy | +7.2% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $772 → $826+7.0% | Buy | +4.5% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $803 → $856+6.6% | Buy | +8.3% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $824 → $875+6.2% | Buy | +10.7% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $737 | Hold | −6.8% | Reiterated | 29.09.26on TipRanks 07:09 | 0.0%next day +1.2% · 5 days −3.5% | ↗ |
| Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% | Wells Fargo | $750 | Hold | −5.2% | Reiterated | 28.09.26on TipRanks Sep 29 05:31 | −3.8%next day 0.0% · 5 days −4.6% | ↗ |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $740 | Hold | −6.4% | Reiterated | 28.09.26on TipRanks 11:55 | −3.8%next day 0.0% · 5 days −4.6% | ↗ |
| Eve Burstein★★★★★★★★★★#1300 · hits 72% · avg +25.0% | Bernstein | $756 | Hold | −4.4% | Reiterated | 25.09.26on TipRanks Sep 26 08:55 | −1.5%next day −3.8% · 5 days −6.5% | ↗ |
| Chris Schott★★★★★★★★★★#1915 · hits 58% · avg +5.7% | J.P. Morgan | $900 | Buy | +13.8% | Reiterated | 25.09.26on TipRanks Sep 26 08:40 | −1.5%next day −3.8% · 5 days −6.5% | ↗ |
| Rajesh Kumar★★★★★★★★★★#1587 · hits 62% · avg +14.5% | HSBC | $800 → $920+15.0% | Buy | +16.3% | Reiterated | 10.09.26on TipRanks 06:35 | −1.2%next day −2.3% · 5 days −1.1% | ↗ |
| Louise Chen★★★★★★★★★★#1899 · hits 52% · avg +5.9% | Scotiabank | $770 | Hold | −2.6% | Reiterated | 20.08.26on TipRanks 09:25 | −0.8%next day +0.5% · 5 days −3.4% | ↗ |
| Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% | BMO Capital | $800 | Buy | +1.2% | Reiterated | 17.08.26on TipRanks Aug 18 07:35 | +0.8%next day +1.3% · 5 days +4.1% | ↗ |
| David Risinger★★★★★★★★★★#64 · hits 65% · avg +33.1% | Leerink Partners | $641 → $824+28.5% | Hold | +4.2% | Reiterated | 17.08.26on TipRanks 06:28 | +0.8%next day +1.3% · 5 days +4.1% | ↗ |
| Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% | Barclays | $917 | Buy | +16.0% | Reiterated | 05.08.26on TipRanks 04:13 | +1.2%next day +0.6% · 5 days +3.5% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | $1,000 → $1,030+3.0% | Buy | +30.3% | Reiterated | 03.08.26on TipRanks 09:35 | −1.9%next day −1.6% · 5 days +4.4% | ↗ |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | $769 → $772+0.4% | Buy | −2.4% | Reiterated | 31.07.26on TipRanks 07:36 | +2.6%next day −1.9% · 5 days −0.7% | ↗ |
| Brian Skorney★★★★★★★★★★#12116 · hits 37% · avg −5.6% | Robert W. Baird | $742 → $761+2.6% | Hold | −3.8% | Reiterated | 31.07.26on TipRanks 07:33 | +2.6%next day −1.9% · 5 days −0.7% | ↗ |
| Terence Flynn★★★★★★★★★★#815 · hits 60% · avg +10.8% | Morgan Stanley | $730 → $758+3.8% | Hold | −4.1% | Reiterated | 31.07.26on TipRanks 07:22 | +2.6%next day −1.9% · 5 days −0.7% | ↗ |
| Carter Gould★★★★★★★★★★#2194 · hits 53% · avg +6.3% | Cantor Fitzgerald | $750 → $795+6.0% | Buy | +0.5% | Reiterated | 30.07.26on TipRanks Jul 31 08:19 | +4.5%next day +2.6% · 5 days +1.0% | ↗ |
| Salveen Richter★★★★★★★★★★#967 · hits 51% · avg +12.5% | Goldman Sachs | $965 → $972+0.7% | Buy | +22.9% | Reiterated | 30.07.26on TipRanks Jul 31 08:06 | +4.5%next day +2.6% · 5 days +1.0% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $856 → $891+4.1% | Buy | +12.7% | Reiterated | 30.07.26on TipRanks Jul 31 05:33 | +4.5%next day +2.6% · 5 days +1.0% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | $960 | Buy | +21.4% | Reiterated | 30.07.26on TipRanks Jul 31 03:46 | +4.5%next day +2.6% · 5 days +1.0% | ↗ |
| John Newman★★★★★★★★★★#3035 · hits 44% · avg +4.1% | Canaccord Genuity | $875 | Buy | +10.7% | Reiterated | 22.07.26on TipRanks Jul 24 05:12 | −3.4%next day +1.3% · 5 days +9.2% | ↗ |
| Biren Amin★★★★★★★★★★#1671 · hits 46% · avg +7.6% | Piper Sandler | $854 | Buy | +8.0% | Assigned | 09.07.26on TipRanks 08:02 | −0.1%next day −0.9% · 5 days +1.8% | ↗ |
| Alexandria Hammond★★★★★★★★★★#7870 · hits 50% · avg +0.6% | Wolfe Research | $860 | Buy | +8.8% | Reiterated | 18.05.26on TipRanks 14:55 | −9.8%next day +0.8% · 5 days −0.7% | ↗ |
| Cory Kasimov★★★★★★★★★★#276 · hits 59% · avg +18.9% | Evercore ISI | $875 → $825−5.7% | Buy | +4.3% | Reiterated | 18.05.26on TipRanks 08:50 | −9.8%next day +0.8% · 5 days −0.7% | ↗ |
| Matthew Biegler★★★★★★★★★★#3953 · hits 39% · avg +3.4% | Oppenheimer | $865 | Buy | +9.4% | Reiterated | 30.04.26on TipRanks 08:35 | +2.0%next day −1.1% · 5 days −1.5% | ↗ |
| Akash Tewari★★★★★★★★★★#649 · hits 57% · avg +13.5% | Jefferies | $885 → $890+0.6% | Buy | +12.6% | Reiterated | 11.03.26on TipRanks 09:25 | +0.5%next day −2.1% · 5 days −1.7% | |
| Christopher Raymond★★★★★★★★★★#4074 · hits 45% · avg +2.6% | Raymond James | $870 | Buy | +10.0% | Reiterated | 30.01.26on TipRanks 15:35 | −0.8%next day +1.3% · 5 days +6.1% | ↗ |
| Nico Chen★★★★★★★★★★#2913 · hits 59% · avg +9.8% | DBS | $910 | Buy | +15.1% | Reiterated | 22.01.26on TipRanks 04:25 | +0.3%next day −0.3% · 5 days −1.5% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Regeneron
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $849 at a price of $758 (+12.0%); now: $864 at $791 (+9.2%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 0 | 0 | 0 |
| Buy | 27 | 23 | 21 | 14 | 17 | 14 |
| Hold | 17 | 15 | 16 | 15 | 20 | 19 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 30.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $16.06 (from $14.78 to $17.68). Last quarter: $14.29.
Sales
Next quarter’s sales estimate — $4.5B (from $4.4B to $4.7B). Last quarter: $4.3B.
Best top-analyst consensus in the sector · Healthcare
About Regeneron
- CEO: Leonard S. Schleifer
- Employees: 15,410
- 777 Old Saw Mill River Road, Tarrytown, NY, 10591-6707, US
- www.regeneron.com
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such
Data from the stock’s TipRanks forecast page, read 2 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗